HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical studies of cefoxitin for the treatment of septicemia (author's transl)].

Abstract
Laboratory studies of CFX were performed on susceptibility of 123 strains isolated from 72 patients with septicemia by disc sensitivity method in comparison with CER and ABPC. Antibacterial activity of CFX was superior against Escherichia coli, Klebsiella, Serratia marcescens and Proteus than that of CER and ABPC, especially against Serratia marcescens and Bacteroides which were mostly resistant to CER and ABPC. CFX was administrated to 8 patients with septicemia. Clinical effects were obtained, excellent and good in 5 patients and poor in 3, and effective rate was 63%. No side effects were observed. The above results indicate that CFX is mainly useful in the treatment of infections caused by Gram-negative bacilli, especially resistant to penicillins, cephalosporins, and Bacteroides.
AuthorsS Yoshida, K Katsurada, K Matsuoka
JournalThe Japanese journal of antibiotics (Jpn J Antibiot) Vol. 34 Issue 9 Pg. 1299-306 (Sep 1981) ISSN: 0368-2781 [Print] Japan
PMID7328752 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Cefoxitin
Topics
  • Adolescent
  • Adult
  • Aged
  • Bacteria (drug effects, isolation & purification)
  • Cefoxitin (therapeutic use)
  • Drug Evaluation
  • Drug Resistance, Microbial
  • Female
  • Humans
  • Male
  • Middle Aged
  • Sepsis (drug therapy, microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: